Radiotherapy and Oncology

Contents

Radiotherapy and Oncology is a peer-reviewed medical journal and an area of clinical practice focusing on the use of ionizing radiation to treat neoplastic disease. The field intersects with institutions such as European Society for Radiotherapy and Oncology, American Society for Radiation Oncology, International Atomic Energy Agency, World Health Organization, and journals like The Lancet, New England Journal of Medicine, Nature, Science.

History and development

The development of radiotherapeutic practice traces roots through figures and events linked to Marie Curie, Wilhelm Röntgen, Ernest Rutherford, Pierre Curie, and the Manhattan Project, while institutions such as Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, University of Cambridge, Johns Hopkins Hospital and Mayo Clinic advanced clinical adoption. Early clinical reports appeared alongside contemporaneous works from Royal Society, Institut Curie, Karolinska Institutet, and the National Institutes of Health; milestones include implementation of cobalt-60 units influenced by Bhabha Atomic Research Centre and introduction of linear accelerators developed at Varian Medical Systems and Siemens Healthineers. The evolution of practice was recorded in proceedings of American Cancer Society, European Organisation for Research and Treatment of Cancer, Academy of Medical Sciences (UK), and meetings at ASCO Annual Meeting and ESTRO Congress.

Radiobiological principles draw upon experiments and theories originating with researchers from Harvard Medical School, University of Oxford, Cold Spring Harbor Laboratory, and Massachusetts Institute of Technology; key concepts include DNA damage responses elucidated by work associated with Francis Crick, James Watson, Barbara McClintock, and Kary Mullis. The four Rs of radiobiology—repair, reassortment, repopulation, and reoxygenation—were refined through studies at Dana-Farber Cancer Institute, Scripps Research Institute, Fred Hutchinson Cancer Center, and Sloan Kettering Institute, while molecular determinants such as p53 pathways connect to research at St. Jude Children's Research Hospital and Cold Spring Harbor Laboratory. Radiosensitivity profiling and biomarkers link to translational programs at MD Anderson Cancer Center, Barcelona Clinic Oncology Institute, and Karolinska University Hospital.

Technological progress involves devices and methods developed by Varian Medical Systems, Elekta AB, IBA (company), and Accuray Inc. Techniques include external beam radiotherapy modalities like three-dimensional conformal radiotherapy traced to work at Massachusetts General Hospital, intensity-modulated radiotherapy adopted at Stanford University, volumetric modulated arc therapy from teams at Vancouver General Hospital, stereotactic radiosurgery influenced by Gamma Knife pioneers at Karolinska Institutet and University of Pittsburgh Medical Center, and particle therapy advances at CERN, GSI Helmholtz Centre, HIT (Heidelberg Ion-Beam Therapy Center), and Proton Therapy Center Massachusetts General Hospital. Imaging integration uses standards from European Society of Radiology, American College of Radiology, Radiological Society of North America, and collaborations with Siemens Healthineers and Philips Healthcare.

Indications for radiotherapy span tumors managed at Royal Marsden Hospital, MD Anderson Cancer Center, Gustave Roussy, Institut Curie, and Moffitt Cancer Center, including head and neck cancers treated per protocols from National Comprehensive Cancer Network, American Joint Committee on Cancer, and European Society for Medical Oncology. Common sites encompass breast cancer guidelines from UK National Health Service, prostate cancer trials from ProtecT (trial), lung cancer strategies discussed at IASLC (International Association for the Study of Lung Cancer), and central nervous system protocols influenced by Glioma Studies Group and Children's Oncology Group. Emerging indications involve oligometastatic Disease concepts promoted by investigators at Belgian Cancer Registry, University of Oxford, and Memorial Sloan Kettering Cancer Center.

Treatment planning relies on software and workflows originating with vendors such as Elekta AB, Varian Medical Systems, and RaySearch Laboratories, integrating imaging from GE Healthcare, Philips Healthcare, and Siemens Healthineers. Quality assurance frameworks reference committees and organizations including International Commission on Radiation Units and Measurements, International Commission on Radiological Protection, National Council on Radiation Protection and Measurements, and regulatory agencies like US Food and Drug Administration and European Medicines Agency. Multimodality workflows are implemented at centers like Mayo Clinic, Johns Hopkins Hospital, Royal Marsden Hospital, and Massachusetts General Hospital with contributions from clinical physicists trained through programs at University of Toronto, King's College London, and University of California, San Francisco.

Toxicity management frameworks derive evidence from trials and cohorts coordinated by EORTC (European Organisation for Research and Treatment of Cancer), RTOG (Radiation Therapy Oncology Group), NRG Oncology, and Children's Oncology Group. Acute and late effects observed in populations treated at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Royal Marsden Hospital inform supportive care delivered in collaboration with American Society of Clinical Oncology, European Society for Medical Oncology, National Comprehensive Cancer Network, and palliative programs at Hospice UK and St. Christopher's Hospice. Interventions include prophylactic, rehabilitative, and pharmacologic strategies guided by investigators at Dana-Farber Cancer Institute, Cleveland Clinic, and Mount Sinai Health System.

Contemporary practice emphasizes multidisciplinary teams drawn from departments at University College London Hospitals, Johns Hopkins Hospital, MD Anderson Cancer Center, and Princess Margaret Cancer Centre, coordinating surgery from Royal College of Surgeons, systemic therapy from European Society for Medical Oncology, and imaging from Radiological Society of North America. Outcomes research leverages registries and trials from SEER Program, Cancer Research UK, European Cancer Information System, ClinicalTrials.gov, and cooperative groups such as EORTC and NRG Oncology to evaluate survival, quality of life, and cost-effectiveness in collaborations with World Health Organization initiatives and policy units at Organisation for Economic Co-operation and Development.